

From the

INTERNATIONAL SEARCHING AUTHORITY

To: PAIK, Nam-Hoon		PCT			
16th Fl., Woori Bank Bldg., 826-20, Yeoksam-dong, Kangnam-ku Seoul 135-080 Republic of Korea		WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY			
		(PCT Rule 43bis.1)			
		Date of mailing (day/month/year) 09 SEPTEMBER 2004 (09.09.2004)		_	
Applicant's or agent's file reference 218		FOR FURTHER ACTION  See paragraph 2 below			
International application No. PCT/KR2004/001086	International filing date 11 MAY 2004 (11.	05.2004)	Priority date(day/month/year) 06 DECEMBER 2003 (06.12.2003)		
International Patent Classification (IPC) IPC7 C08G 61/00, C12P 1/00 Applicant KOREA RESEARCH INSTITU			Y et al		
Box No. IV Lack of unity of X Box No. V Reasoned statent citations and exp Box No. VI Certain docume Box No. VII Certain defects Box No. VIII Certain observation.  2. FURTHER ACTION If a demand for international preliminary Examining A other than this one to be the IPEA and opinions of this International Searchin.  If this opinion is, as provided above, or IPEA a written reply together, where a	Intions relating to the following items:  of the opinion  y  stablishment of opinion with regard to novelty, inventive step and industrial applicability of unity of invention  ned statement under Rule 43bis. I(a)(i) with regard to novelty, inventive step or industrial applicability; as and explanations supporting such statement and documents cited  note of the international application an observations on the international application  preliminary examination is made, this opinion will be considered to be a written opinion of the amining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority PEA and the chosen IPEA has notified the International Bureau under Rule 66. Ibis(b) that written Searching Authority will not be so considered.  above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the c, where appropriate, with amendments, before the expiration of 3 months from the date of mailing one the expiration of 22 months from the priority date, whichever expires later.  PCT/ISA/220.				

Name and mailing address of the ISA/KF



Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LEE, Suk Ju

Telephone No. 82-42-481-8149



## BEST AVAILABLE COPY

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

international application No.

PCT/KR2004/001086

	A No. 1 Dasis of this opinion	
		-
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.	
	This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).	
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:	
	a. type of material	
	a sequence listing	
	table(s) related to the sequence listing	
	b. format of material	
	in wirtten format	
	in computer readable form	
	c. time of filing/furnishing	
	contained in the international application as filed.	
	filed together with the international application in computer readable form.	
	furnished subsequently to this Authority for the purposes of search.	
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additioanl copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	
4.	Additional comments:	
	<u> </u>	



## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/KR2004/001086

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement			
Novelty (N)	Claims	1-8	YES
	Claims	None	NO
Inventive step (IS)	Claims	1-8	YES
	Claims	None	NO
Industrial applicability (IA)	Claims	1-8	YES
	Claims	None	NO

## 2. Citations and explanations:

Reference is made to the following documents:

D1: US 4,900,671 A D2: US 5,824,414 A D3: JP 2002-201245 A

D1 relates to a process for the preparation of a phenolic resin which comprises reacting a phenol with a peroxidase or an oxidase enzyme and peroxide in an organic solvent containing medium to generate phenolic radicals which react to form a phenolic resin.

D2 relates to phenols reacting with hydrogen peroxide in a solution comprising an organic solvent compatible with water, a peroxide and a dispersing agent to obtain spherical polyphenol particles.

D3 relates to a production method for a solid resol type phenol resin whereby a resol type phenol resin not containing nitrogen component can be easily obtained as a solid.

The subject matter of claims 1-6 differs from the disclosure of D1-D3 mainly in that phenothiazine mediator is used in the process for preparing a phenolic resin.

The subject matter of claims 7-8 differs from the disclosure of D1-D3 mainly in that a phenolic resin manufactured by the method of claims 1-6 has a double bond of lipid group as a side chain.

None of the documents D1-D3 teach or suggest such a phenothiazine mediator, and a phenol resin having a double bond of lipid group as a side chain. In addition, it cannot be considered obvious to a person skilled in the art, with the knowledge of cited documents, to use phenothiazine as a mediator to increase the yield of a phenolic resin. A phenolic resin having a double bond of lipid group as a side chain easily facilitates radical curing reaction, thereby forming film of paint and improving anti-fouling effect.

Therefore, claims 1-8 of the present application are considered to meet the requirement of Article 33(2) and 33(3).